- Oops!Something went wrong.Please try again later.
Shares of Ascendis Pharma (NASDAQ:ASND) were unchanged after the company reported Q2 results.
Earnings per share were down 56.12% year over year to ($2.17), which missed the estimate of ($1.70).
Revenue of $1,581,000 declined by 55.64% year over year, which missed the estimate of $2,530,000.
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Aug 27, 2020
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/w7hnzp6j
Company's 52-week high was at $158.93
Company's 52-week low was at $90.06
Price action over last quarter: down 5.18%
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in the USA, Germany, and Switzerland and derives the majority of its revenue from the US.
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.